Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus propofol, midazolam, dexmedetomidine, and fentanyl alone for bronchoscopy sedation in elderly RICU patients
ChiCTR2100048547Phase 4Not yet recruiting
- Sponsor
- Xinxiang Central Hospital
- Start
- Apr 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, propofol, midazolam, dexmedetomidine and fentanyl (5 arms), sponsored by Xinxiang Central Hospital. Primary endpoints: Modified Observer's Assessment of Alertness/Sedation score immediately after administration, Time to sedation induction and 2 more. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
remimazolampropofolmidazolamdexmedetomidinefentanyl
Beyond the preview
Go deeper on ChiCTR2100048547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048547.